Journal Browser

► Journal Browser

Special Issue "New Advances in Type 2 Diabetes and Its Complications"

Share This Special Issue

Special Issue Editor

Special Issue Information

Dear Colleagues,

I have the honour and privilege of being a Guest Editor for the new Special Issue "New Advances in Type 2 Diabetes and Its Complications".

Type 2 diabetes is one of the most common chronic diseases in modern society. Nevertheless, unfortunately, there are still insufficient research data on the pathogenesis of type 2 diabetes and its complications.

This Special Issue aims to bring forward exciting papers based on the new pathological mechanisms and therapeutic discoveries related to type 2 diabetes and its complications. Therefore, we encourage you to submit original research and review articles regarding recent advances in diabetes pathophysiology and new therapeutic molecules, as well as those related to cardiovascular disease, stroke, neuropathy, retinopathy, chronic kidney disease or non-alcoholic fatty liver disease in patients with type 2 diabetes.

Thank you in advance for your interest.

Dr. Anca Pantea Stoian
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

diabetes type 2
diabetes complications
pathophysiology of type 2 diabetes
new diabetes treatment
cardiovascular disease
stroke
peripheral artery disease
chronic kidney disease
retinopathy
neuropathy
non-alcoholic fatty liver disease in diabetes

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Review

19 pages, 2676 KiB

Open AccessReview

Natural Inhibitors of Mammalian α-Amylases as Promising Drugs for the Treatment of Metabolic Diseases

Aleksandr P. Kalinovskii

Oksana V. Sintsova

Irina N. Gladkikh

and

Elena V. Leychenko

Int. J. Mol. Sci. 2023, 24(22), 16514; https://doi.org/10.3390/ijms242216514 - 20 Nov 2023

Viewed by 524

Abstract

α-Amylase is a generally acknowledged molecular target of a distinct class of antidiabetic drugs named α-glucosidase inhibitors. This class of medications is scarce and rather underutilized, and treatment with current commercial drugs is accompanied by unpleasant adverse effects. However, mammalian α-amylase inhibitors are abundant in nature and form an extensive pool of high-affinity ligands that are available for drug discovery. Individual compounds and natural extracts and preparations are promising therapeutic agents for conditions associated with impaired starch metabolism, e.g., diabetes mellitus, obesity, and other metabolic disorders. This review focuses on the structural diversity and action mechanisms of active natural products with inhibitory activity toward mammalian α-amylases, and emphasizes proteinaceous inhibitors as more effective compounds with significant potential for clinical use. Full article

(This article belongs to the Special Issue New Advances in Type 2 Diabetes and Its Complications)

► Show Figures

Figure 1

16 pages, 1736 KiB

Open AccessReview

A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis

Teodor Salmen

Liviu-Ionut Serbanoiu

Ioana-Cristina Bica

Cristian Serafinceanu

and

Int. J. Mol. Sci. 2023, 24(11), 9760; https://doi.org/10.3390/ijms24119760 - 05 Jun 2023

Cited by 2 | Viewed by 1783

Abstract

The increase in life expectancy without a decrease in the years lived without disability leads to the rise of the population aged over 65 years prone to polypharmacy. The novel antidiabetic drugs can improve this global therapeutic and health problem in patients with diabetes mellitus (DM). We aimed to establish the efficacy (A1c hemoglobin reduction) and safety of the newest antidiabetic drugs (considered so due to their novelty in medical practice use), specifically DPP-4i, SGLT-2i, GLP-1 Ra, and tirzepatide. The present meta-analysis followed the protocol registered at Prospero with the CRD42022330442 registration number. The reduction in HbA1c in the DPP4-i class for tenegliptin was 95% CI −0.54 [−1.1, 0.01], p = 0.06; in the SGLT2-iclass for ipragliflozin 95% CI −0.2 [−0.87, 0.47], p = 0.55; and for tofogliflozin 95% CI 3.13 [−12.02, 18.28], p = 0.69, while for tirzepatide it was 0.15, 95% CI [−0.50, 0.80] (p = 0.65). The guidelines for treatment in type 2 DM are provided from cardiovascular outcome trials that report mainly major adverse cardiovascular events and data about efficacy. The newest antidiabetic non-insulinic drugs are reported to be efficient in lowering HbA1c, but this effect depends between classes, molecules, or patients’ age. The newest antidiabetic drugs are proven to be efficient molecules in terms of HbA1c decrease, weight reduction, and safety, but more studies are needed in order to characterize exactly their efficacy and safety profiles. Full article

(This article belongs to the Special Issue New Advances in Type 2 Diabetes and Its Complications)

► Show Figures

Journal Menu

Journal Browser

Special Issue "New Advances in Type 2 Diabetes and Its Complications"

Share This Special Issue

Special Issue Editor

Special Issue Information

Keywords

Published Papers (2 papers)

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI